On April 22, 2204 Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to specifically treat metastatic breast cancers (mBC) harboring ESR1 mutations, reported it will host a virtual KOL fireside chat on Monday, April 22, 2024 from 12:00 PM to 1:00 PM ET, featuring Senthil Damodaran MD, PhD (MD Anderson Cancer Center) and Seth Wander, MD, PhD (Harvard Medical School, Massachusetts General Hospital) to discuss the unmet need and current treatment landscape for metastatic breast cancer (Press release, Sermonix Pharmaceuticals, APR 22, 2024, View Source [SID1234642204]). To register, click here.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The event will focus on the Company’s ELAINE (Evaluating Lasofoxifene in ESR1 Mutations) studies investigating lasofoxifene in patients with locally advanced or metastatic estrogen receptor-positive/human epidermal growth factor 2-negative (ER+/HER2-) breast cancer expressing an estrogen receptor 1 (ESR1) mutation.

With Phase 2 ELAINE-1 and ELAINE-2 studies both completed and having demonstrated compelling anti-tumor activity against tumors with increasingly prevalent ESR1 mutations, enrollment is currently open for ELAINE-3, a large, randomized, Phase 3 study with clinical trial sites across the United States, Europe, Asia-Pacific, Israel, and Canada.

A live question and answer session will follow the formal presentations.